$1,000 Invested in Aurora Cannabis at the Start of 2022 Would Be Worth This Much Today

Aurora Cannabis stock is down almost 80% in 2022. Can ACB stock stage a comeback and outpace the TSX index in 2023?

| More on:
A person holds a small glass jar of marijuana.

Source: Getty Images

Despite its volatility, Aurora Cannabis (TSX:ACB) has been among the most popular stocks on the TSX, with an average daily trading volume of three million. While ACB stock generated exponential returns just before pot was legalized for recreational use in Canada four years back, it has since trailed the broader markets by a wide margin.

Here, let’s see how much a $1,000 investment in Aurora Cannabis stock at the start of 2022 will be worth today.

Aurora Cannabis stock outpaced the TSX in 2018

Shares of Aurora Cannabis surged over 50,000% between December 2013 and October 2018. So, an investment of $1,000 in ACB stock would be worth $500,000 in fewer than five years. But once Canada legalized cannabis at the federal level in October 2018, the selloff in ACB stock has been extremely painful for shareholders.

In the last 50 months, Aurora Cannabis has been impacted by a range of industry-wide issues that include rising competition, a thriving black market, lower-than-expected demand, rising inventory levels, and massive losses.

In order to sustain its high cash-burn rate and aggressive acquisitions, Aurora Cannabis raised equity capital several times in recent years, diluting shareholder wealth in the process.

The selloff surrounding the stock market in 2022 has dragged ACB stock lower by 79% year to date. So, an investment of $1,000 in Aurora Cannabis at the start of 2022 would be worth $220.4 today.

ACB has been among the worst-performing cannabis stocks on the TSX and is down 99% from all-time highs. But past performance should not matter much to current and future investors. Let’s see if Aurora Cannabis stock can stage a comeback in 2023.

Can ACB stock beat the TSX in 2023?

While the Canadian cannabis market continues to expand, Aurora Cannabis is forecast to report revenue of $196 million in fiscal 2023 — a decline of 11.4% year over year. The company is now looking to shut down facilities to lower costs. It has also focused on gaining market share in the high-margin medical marijuana business to limp toward profitability.

The main driver for Aurora Cannabis and peers will be the eventual legalization of cannabis south of the border. While marijuana is legal in a few states in the U.S., it remains illegal at the federal level. The United States will provide Aurora Cannabis with access to a far larger market and drive sales via acquisitions as well.

In the near term, Aurora Cannabis needs to strengthen its balance sheet and regain investor confidence. In the fiscal first quarter of 2023 (ended in September), its sales fell 18% year over year to $50 million. The company’s adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) loss stood at $8.7 million, as it used $31.1 million to fund its operations in the quarter. In the last 12 months, its net loss stood at $1.8 billion, while total revenue was $210 million.

Aurora ended the first quarter with a cash balance of $369 million, providing it with enough room to improve the bottom line. But looking at its track record, Aurora Cannabis has failed to achieve its financial goals consistently in the past, making it a high-risk bet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »